Symrise Ag

Bitop Ag

Symrise Gmbh & Co Kg

Lycored Ltd.

Blaa Lonid Hf

Bitop Aktiengesellschaft Für Biotechnische Optimierung

Jean Krutmann

Imke Meyer

Gerhard Schmaus

William Johncock

Marielle Le Maire

Martina Herrmann

Oskar Koch

Thomas Schwarz

Georg Lentzen

Gabriele Vielhaber

Yoav Sharoni

Joseph Levy

Sigurbjorn Einarsson

Asa Brynjolfsdottir

Karin Linnewiel Hermoni

Andreas Bilstein

Klaus Unfried

Ulrich Sydlik

The invention is directed to compositions comprising lycopene and to methods of using the same, such as for improving one or more skin parameters. e.g., prevention or treatment of various skin-related conditions caused by ultraviolet radiation.

Lycopene compositions and methods for protecting skin against ultraviolet radiation

Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of purple coneflower pressed juice, sclareolide, ginger root C02 extract, E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.

Cosmetic compositions comprising purple coneflower pressed juice

Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one, sclareolide, purple coneflower pressed juice, ginger root CO2 extract or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.

Cosmetic compositions

Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of ginger root C02 extract, E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one, sclareolide, purple coneflower pressed juice or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.

Cosmetic compositions comprising ginger root extracts

Suggested is a cosmetic composition comprising an anti-pollution agent selected from the group consisting of sclareolide, ginger root CO2 extract, E/Z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one, purple coneflower pressed juice or mixtures thereof, in a working amount sufficient for (a) reducing or preventing air pollution induced gene expression, and/or (b) reducing or preventing a gene expression induced or inducible by polycyclic aromatic hydrocarbons, and/or (c) reducing or preventing air pollution-induced or air pollution-inducible skin damage.

Cosmetic compositions comprising sclareolide

The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), &#x3b2;-mannosylglycerate (firoin), &#x3b2;-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well.

Method of using compatible solutes containing ectoine and/or hydroxyectoine

This invention relates to cosmetic and pharmaceutical preparations comprising 

Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol

The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis.

Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis

The invention provides the use of extracts from algae for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that extracts from algae obtainable from saline hot water sources exhibit a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that such algae extracts induce markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induce collagen expression in dermal fibroblasts and inhibit UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6).

Pharmaceutical and cosmetic use of extracts from algae obtainable from saline hot water sources

The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances, more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1,3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), &#x3b2;-mannosylglycerate (firoin), &#x3b2;-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds.

Osmolytes for the treatment of allergic or viral respiratory diseases

The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses.

Growing community of inventors

Wegberg, Germany

Jean Krutmann